PURPOSE: To estimate the cancer incidences and mortalities in China in 2010. METHODS: On basis of the evaluation procedures and data quality criteria described in the National Central Cancer Registry (NCCR), data from 219 cancer registries were evaluated. Data from 145 registries were identified as qualified and then accepted for the 2010 cancer registry report. The incidences and mortalities of major cancers and the overall incidence and mortality were stratified by residency (urban or rural), areas (eastern, middle, and western), gender, and age. The cancer cases and deaths were estimated based on age-specific rate and national population in 2010. The China 2010 Population Census data and Segi's world population data were used for calculating the age-standardized cancer incidence/mortality rates. RESULTS: Data were obtained from a total of 145 cancer registries (63 in urban areas and 82 in rural areas) covering 158,403,248 people (92,433,739 in urban areas and 65,969,509 in rural areas). The percentage of morphologically verified cases (MV%) were 67.11%; 2.99% of incident cases were identified through proportion of death certification only (DCO%), with the mortality to incidence ratio of (M/I) 0.61. The estimates of new cancer cases and cancer deaths were 3,093,039 and 1,956,622 in 2010, respectively. The crude incidence was 235.23/10(5) (268.65/10(5) in males and 200.21/10(5) in females), the age-standardized rates by Chinese standard population (ASR China) and by world standard population (ASR world) were 184.58/10(5) and 181.49/10(5), and the cumulative incidence rate (0-74 age years old) was 21.11%. The cancer incidence and ASR China were 256.41/10(5) and 187.53/10(5) in urban areas and 213.71/10(5) and 181.10/10(5) in rural areas. The crude cancer mortality in China was 148.81/10(5) (186.37/10(5) in males and 109.42/10(5) in females), the age-standardized mortalities by Chinese standard population and by world standard population were 113.92/10(5) and 112.86/10(5), and the cumulative mortality rate (0-74 age years old) was 12.78%. The cancer mortality and ASR China were 156.14/10(5) and 109.21/10(5) in urban areas 141.35/10(5) and 119.00/10(5) in rural areas, respectively. Lung cancer, female breast cancer, gastric cancer, liver cancer, esophageal cancer, colorectal cancer, and cervical cancer were the most common cancers. Lung cancer, liver cancer, gastric cancer, esophageal cancer, colorectal cancer, breast cancer, and pancreatic cancer were the leading causes of cancer deaths. CONCLUSIONS: The coverage of cancer registration has rapidly increased in China in recent years and may reflect more accurate cancer burdens among populations living in different areas. As the basis of cancer control program, cancer registration plays an irreplaceable role in cancer surveillance, intervention evaluation, and policy-making. Given the increasing cancer burden in the past decades, China should strengthen its cancer prevention and control.
PURPOSE: To estimate the cancer incidences and mortalities in China in 2010. METHODS: On basis of the evaluation procedures and data quality criteria described in the National Central Cancer Registry (NCCR), data from 219 cancer registries were evaluated. Data from 145 registries were identified as qualified and then accepted for the 2010 cancer registry report. The incidences and mortalities of major cancers and the overall incidence and mortality were stratified by residency (urban or rural), areas (eastern, middle, and western), gender, and age. The cancer cases and deaths were estimated based on age-specific rate and national population in 2010. The China 2010 Population Census data and Segi's world population data were used for calculating the age-standardized cancer incidence/mortality rates. RESULTS: Data were obtained from a total of 145 cancer registries (63 in urban areas and 82 in rural areas) covering 158,403,248 people (92,433,739 in urban areas and 65,969,509 in rural areas). The percentage of morphologically verified cases (MV%) were 67.11%; 2.99% of incident cases were identified through proportion of death certification only (DCO%), with the mortality to incidence ratio of (M/I) 0.61. The estimates of new cancer cases and cancer deaths were 3,093,039 and 1,956,622 in 2010, respectively. The crude incidence was 235.23/10(5) (268.65/10(5) in males and 200.21/10(5) in females), the age-standardized rates by Chinese standard population (ASR China) and by world standard population (ASR world) were 184.58/10(5) and 181.49/10(5), and the cumulative incidence rate (0-74 age years old) was 21.11%. The cancer incidence and ASR China were 256.41/10(5) and 187.53/10(5) in urban areas and 213.71/10(5) and 181.10/10(5) in rural areas. The crude cancer mortality in China was 148.81/10(5) (186.37/10(5) in males and 109.42/10(5) in females), the age-standardized mortalities by Chinese standard population and by world standard population were 113.92/10(5) and 112.86/10(5), and the cumulative mortality rate (0-74 age years old) was 12.78%. The cancer mortality and ASR China were 156.14/10(5) and 109.21/10(5) in urban areas 141.35/10(5) and 119.00/10(5) in rural areas, respectively. Lung cancer, female breast cancer, gastric cancer, liver cancer, esophageal cancer, colorectal cancer, and cervical cancer were the most common cancers. Lung cancer, liver cancer, gastric cancer, esophageal cancer, colorectal cancer, breast cancer, and pancreatic cancer were the leading causes of cancer deaths. CONCLUSIONS: The coverage of cancer registration has rapidly increased in China in recent years and may reflect more accurate cancer burdens among populations living in different areas. As the basis of cancer control program, cancer registration plays an irreplaceable role in cancer surveillance, intervention evaluation, and policy-making. Given the increasing cancer burden in the past decades, China should strengthen its cancer prevention and control.
Entities:
Keywords:
Cancer registry; China; incidence; malignant tumor; mortality
Authors: Xiao-Wei Qi; Xiao-Dong Zheng; Bei-Ge Zong; Qing-Qiu Chen; Fan Zhang; Xin-Hua Yang; Yi Zhang; Jun-Lan Liu; Jun Jiang Journal: Am J Cancer Res Date: 2015-02-15 Impact factor: 6.166